TG Therapeutics (NASDAQ:TGTX) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of TG Therapeutics (NASDAQ:TGTX – Free Report) from a hold rating to a buy rating in a research report released on Saturday morning.

A number of other research analysts have also recently commented on the company. HC Wainwright began coverage on TG Therapeutics in a report on Monday, October 6th. They issued a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of TG Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Finally, B. Riley raised shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $50.25.

Check Out Our Latest Stock Report on TG Therapeutics

TG Therapeutics Trading Down 6.0%

Shares of TG Therapeutics stock opened at $30.30 on Friday. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The company has a market capitalization of $4.81 billion, a P/E ratio of 81.89 and a beta of 1.95. The company has a fifty day moving average of $33.93 and a 200 day moving average of $34.57.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The business had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s quarterly revenue was up 92.7% on a year-over-year basis. During the same period last year, the firm earned $0.02 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total transaction of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently added to or reduced their stakes in TGTX. State Street Corp lifted its stake in shares of TG Therapeutics by 2.5% in the 2nd quarter. State Street Corp now owns 7,618,238 shares of the biopharmaceutical company’s stock valued at $274,180,000 after purchasing an additional 184,339 shares during the last quarter. Geode Capital Management LLC lifted its position in TG Therapeutics by 6.3% in the second quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after buying an additional 207,890 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock worth $75,683,000 after buying an additional 345,059 shares during the period. Hood River Capital Management LLC increased its position in TG Therapeutics by 0.7% during the second quarter. Hood River Capital Management LLC now owns 1,567,506 shares of the biopharmaceutical company’s stock valued at $56,415,000 after acquiring an additional 11,018 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in TG Therapeutics by 1,809.9% during the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after acquiring an additional 1,149,526 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

(Get Free Report)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Read More